Zydus Lifesciences to commercialize OncoStem’s CanAssist Breast test
Zydus Lifesciences has secured exclusive marketing rights to CanAssist Breast, a prognostic test for breast cancer patients in the early stages, from Bengaluru-based OncoStem.
According to Zydus Lifesciences, CanAssist Breast will enable clinicians in taking a call if the patient requires chemotherapy or not.
By leveraging OncoStem’s proprietary artificial intelligence/machine learning methods, CanAssist Breast can optimize the selection of treatment in early stage (I and II) hormone receptor positive, HER2 receptor negative type of breast cancer. The prognostic test determines the risk of recurrence in breast cancer patients and classifies them as ‘low risk’ or ‘high risk’.
Zydus Lifesciences to commercialize OncoStem’s CanAssist Breast test. Photo courtesy of Zydus Cadila.
Dr. Sharvil Patel — Zydus Lifesciences Managing Director said: “Zydus has been at the forefront of providing access to innovative and affordable therapies which also helps improve the quality of care for cancer patients in India.
“With this new offering we expand our offerings to include prognostic and diagnostic approaches that can greatly benefit cancer patients and clinicians. As a company dedicated to science, innovation and health, we are constantly looking at ways to empower people to live healthier and more fulfilled lives.”